Annual CFF
$90.31 M
+$74.53 M+472.08%
December 31, 2024
Summary
- As of March 12, 2025, NVCR annual cash flow from financing activities is $90.31 million, with the most recent change of +$74.53 million (+472.08%) on December 31, 2024.
- During the last 3 years, NVCR annual CFF has risen by +$64.61 million (+251.39%).
- NVCR annual CFF is now -79.48% below its all-time high of $440.21 million, reached on December 31, 2020.
Performance
NVCR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.69 M
+$2.58 M+2585.00%
December 31, 2024
Summary
- As of March 12, 2025, NVCR quarterly cash flow from financing activities is $2.69 million, with the most recent change of +$2.58 million (+2585.00%) on December 31, 2024.
- Over the past year, NVCR quarterly CFF has stayed the same.
- NVCR quarterly CFF is now -99.53% below its all-time high of $570.85 million, reached on December 31, 2020.
Performance
NVCR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$90.31 M
+$775.00 K+0.87%
December 31, 2024
Summary
- As of March 12, 2025, NVCR TTM cash flow from financing activities is $90.31 million, with the most recent change of +$775.00 thousand (+0.87%) on December 31, 2024.
- Over the past year, NVCR TTM CFF has stayed the same.
- NVCR TTM CFF is now -84.77% below its all-time high of $592.90 million, reached on September 30, 2021.
Performance
NVCR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NVCR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +472.1% | 0.0% | 0.0% |
| 3 y3 years | +251.4% | -26.5% | +251.4% |
| 5 y5 years | +46.4% | -68.7% | +46.4% |
NVCR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +483.0% | -96.9% | +2585.0% | -0.3% | +736.6% |
| 5 y | 5-year | -79.5% | +483.0% | -99.5% | +101.9% | -84.8% | +174.0% |
| alltime | all time | -79.5% | +4110.5% | -99.5% | +101.9% | -84.8% | +174.0% |
NovoCure Limited Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $90.31 M(+472.1%) | $2.69 M(+2585.0%) | $90.31 M(+0.9%) |
| Sep 2024 | - | $100.00 K(-99.9%) | $89.54 M(-1.2%) |
| Jun 2024 | - | $87.32 M(>+9900.0%) | $90.61 M(+739.3%) |
| Mar 2024 | - | $213.00 K(-88.8%) | $10.80 M(-31.6%) |
| Dec 2023 | $15.79 M(+1.9%) | $1.91 M(+63.1%) | $15.79 M(-8.7%) |
| Sep 2023 | - | $1.17 M(-84.4%) | $17.29 M(-14.9%) |
| Jun 2023 | - | $7.50 M(+44.2%) | $20.32 M(+15.8%) |
| Mar 2023 | - | $5.20 M(+52.6%) | $17.55 M(+13.3%) |
| Dec 2022 | $15.49 M(-39.7%) | $3.41 M(-18.9%) | $15.49 M(-1.5%) |
| Sep 2022 | - | $4.20 M(-11.2%) | $15.73 M(+8.0%) |
| Jun 2022 | - | $4.74 M(+50.8%) | $14.56 M(-30.3%) |
| Mar 2022 | - | $3.14 M(-14.0%) | $20.89 M(-18.7%) |
| Dec 2021 | $25.70 M(-94.2%) | $3.65 M(+20.3%) | $25.70 M(-95.7%) |
| Sep 2021 | - | $3.04 M(-72.5%) | $592.90 M(+31.9%) |
| Jun 2021 | - | $11.06 M(+39.0%) | $449.38 M(+1.3%) |
| Mar 2021 | - | $7.96 M(-98.6%) | $443.66 M(+0.8%) |
| Dec 2020 | $440.21 M(+613.7%) | $570.85 M(-506.3%) | $440.21 M(-460.7%) |
| Sep 2020 | - | -$140.49 M(-2728.5%) | -$122.06 M(-460.0%) |
| Jun 2020 | - | $5.34 M(+18.7%) | $33.90 M(-31.1%) |
| Mar 2020 | - | $4.50 M(-47.6%) | $49.21 M(-20.2%) |
| Dec 2019 | $61.68 M | $8.59 M(-44.5%) | $61.68 M(+10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | $15.47 M(-25.1%) | $55.66 M(+26.2%) |
| Jun 2019 | - | $20.66 M(+21.7%) | $44.09 M(+27.3%) |
| Mar 2019 | - | $16.97 M(+561.6%) | $34.63 M(-50.1%) |
| Dec 2018 | $69.37 M(+1242.3%) | $2.56 M(-34.3%) | $69.37 M(+1.8%) |
| Sep 2018 | - | $3.90 M(-65.1%) | $68.13 M(+3.3%) |
| Jun 2018 | - | $11.19 M(-78.4%) | $65.94 M(+16.1%) |
| Mar 2018 | - | $51.71 M(+3791.2%) | $56.82 M(+999.5%) |
| Dec 2017 | $5.17 M(-93.1%) | $1.33 M(-22.4%) | $5.17 M(+0.0%) |
| Sep 2017 | - | $1.71 M(-17.1%) | $5.17 M(-93.2%) |
| Jun 2017 | - | $2.07 M(+3403.4%) | $76.31 M(+1.6%) |
| Mar 2017 | - | $59.00 K(-95.6%) | $75.14 M(+0.0%) |
| Dec 2016 | $75.12 M(-72.9%) | $1.33 M(-98.2%) | $75.12 M(-68.0%) |
| Sep 2016 | - | $72.85 M(+7976.8%) | $235.05 M(+46.2%) |
| Jun 2016 | - | $902.00 K(+2100.0%) | $160.76 M(-36.5%) |
| Mar 2016 | - | $41.00 K(-100.0%) | $253.24 M(-8.6%) |
| Dec 2015 | $276.99 M(>+9900.0%) | $161.26 M(<-9900.0%) | $276.99 M(+139.3%) |
| Sep 2015 | - | -$1.44 M(-101.5%) | $115.73 M(-1.2%) |
| Jun 2015 | - | $93.39 M(+292.6%) | $117.17 M(+392.6%) |
| Mar 2015 | - | $23.79 M | $23.79 M |
| Dec 2014 | $2.15 M(-98.8%) | - | - |
| Dec 2013 | $183.32 M | - | - |
FAQ
- What is NovoCure Limited annual cash flow from financing activities?
- What is the all time high annual CFF for NovoCure Limited?
- What is NovoCure Limited annual CFF year-on-year change?
- What is NovoCure Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for NovoCure Limited?
- What is NovoCure Limited quarterly CFF year-on-year change?
- What is NovoCure Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for NovoCure Limited?
- What is NovoCure Limited TTM CFF year-on-year change?
What is NovoCure Limited annual cash flow from financing activities?
The current annual CFF of NVCR is $90.31 M
What is the all time high annual CFF for NovoCure Limited?
NovoCure Limited all-time high annual cash flow from financing activities is $440.21 M
What is NovoCure Limited annual CFF year-on-year change?
Over the past year, NVCR annual cash flow from financing activities has changed by +$74.53 M (+472.08%)
What is NovoCure Limited quarterly cash flow from financing activities?
The current quarterly CFF of NVCR is $2.69 M
What is the all time high quarterly CFF for NovoCure Limited?
NovoCure Limited all-time high quarterly cash flow from financing activities is $570.85 M
What is NovoCure Limited quarterly CFF year-on-year change?
Over the past year, NVCR quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is NovoCure Limited TTM cash flow from financing activities?
The current TTM CFF of NVCR is $90.31 M
What is the all time high TTM CFF for NovoCure Limited?
NovoCure Limited all-time high TTM cash flow from financing activities is $592.90 M
What is NovoCure Limited TTM CFF year-on-year change?
Over the past year, NVCR TTM cash flow from financing activities has changed by $0.00 (0.00%)